Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.00 |
|---|---|
| High | 2.50 |
| Low | 2.50 |
| Bid | -- |
| Offer | -- |
| Previous close | 2.50 |
| Average volume | -- |
|---|---|
| Shares outstanding | 120.90m |
| Free float | 111.22m |
| P/E (TTM) | -- |
| Market cap | 199.48m USD |
| EPS (TTM) | -1.15 USD |
Data delayed at least 15 minutes, as of Oct 31 2024 07:07 BST.
More ▼
Announcements
- Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
- Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
- Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
- Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
- Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
- Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
- Inhibikase Announces Expansion of Senior Leadership Team
More ▼
